Future therapy for non-alcoholic fatty liver disease

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

(2016) Scott Friedman et al.   Contemporary Clinical Trials

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

(2016) Jeffrey Cui et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Management of NAFLD: a stage-based approach

(2016) Mary E. Rinella et al.   Nature Reviews Gastroenterology & Hepatology

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels

(2015) Paola Portillo-Sanchez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Statin use and non-alcoholic steatohepatitis in at risk individuals

(2015) Paola Dongiovanni et al.   JOURNAL OF HEPATOLOGY

LP37 : A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases

(2015) M. Shiffman et al.   JOURNAL OF HEPATOLOGY

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

(2015) Curtis K. Argo et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease

(2014) Rifaat Safadi et al.   Clinical Gastroenterology and Hepatology

No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial

(2014) Arun J. Sanyal et al.   GASTROENTEROLOGY

An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice

(2013) Shannon M Reilly et al.   NATURE MEDICINE

Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells

(2012) Divya P. Kumar et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

(2012) I. N. Colmers et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial

(2012) Carmela Loguercio et al.   FREE RADICAL BIOLOGY AND MEDICINE

Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study

(2012) Ali Akbar Hajiaghamohammadi et al.   Hepatitis Monthly

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

(2012) Lixin Zhu et al.   HEPATOLOGY

Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)

(2012) Winston Dunn et al.   JOURNAL OF HEPATOLOGY

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study

(2011) R. M. Williamson et al.   DIABETES CARE

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

(2011) Neeraj Bhala et al.   HEPATOLOGY

Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality

(2011) Zobair M. Younossi et al.   HEPATOLOGY

Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents

(2011) Joel E. Lavine   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis

(2011) Suzanne E. Mahady et al.   JOURNAL OF HEPATOLOGY

Scraping fibrosis: Expressway to the core of fibrosis

(2011) Wajahat Z Mehal et al.   NATURE MEDICINE

Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

(2010) Giovanni Musso et al.   ANNALS OF MEDICINE

Transient elastography for the diagnosis of liver fibrosis

(2010) Victor de Lédinghen et al.   Expert Review of Medical Devices

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

(2010) Mustafa S. Ascha et al.   HEPATOLOGY

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

(2010) Elizabeth M. Brunt et al.   HEPATOLOGY

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

(2010) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

(2009) Charles Thomas et al.   Cell Metabolism

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial

(2009) Manal F. Abdelmalek et al.   HEPATOLOGY

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

(2009) Vincent Wai-Sun Wong et al.   HEPATOLOGY

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH

Effect of Bariatric Surgery on Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

(2008) Rajasekhara R. Mummadi et al.   Clinical Gastroenterology and Hepatology

Visceral fat: A key mediator of steatohepatitis in metabolic liver disease

(2008) David van der Poorten et al.   HEPATOLOGY

The effect of thiazolidinediones on adiponectin serum level: a meta-analysis

(2007) N. Riera-Guardia et al.   DIABETES OBESITY & METABOLISM